COX-2-IN-29

立即咨询

COX-2-IN-29

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品介绍

COX-2-IN-29 (Compound 15b) 是一种选择性的、具有口服活性的COX-2抑制剂，IC₅₀为 0.005 μM。

生物活性

COX-2-IN-29 (Compound 15b) is a selective and orally activeCOX-2inhibitor with anIC₅₀of 0.005 μM^[1].

IC₅₀& Target

COX-2

0.005 μM (IC₅₀)

COX-1

> 10 μM (IC₅₀)

体外研究
(In Vitro)

COX-2-IN-29 (Compound 15b) shows metabolic stability with intrinsic clearance value of 39.9 and 40.3 μL/min/mg protein in mouse and human liver microsomes, respectively^[1].

体内研究
(In Vivo)

COX-2-IN-29 (Compound 15b) (10 and 20 mg/kg; p.o.; once) shows antinociceptive activity at 20 mg/kg, and shows anti-inflammatory and anti-edema activities^[1].

Animal Model:	Male CD1 albino mice (23 – 25 g) or male Sprague–Dawley rats weighing approximately 200 – 250 g^[1]
Dosage:	10 and 20 mg/kg
Administration:	PO, once
Result:	Induced a reduction of the number of writhes in a statistically significant manner at the minimum dose of 20 mg/kg, while didn’t show any antinociceptive efficacy at 10 mg/kg. Showed a good activity against carrageenan-induced hyperalgesia 30 min after administration, disappearing completely at 1 h after treatment. A very good activity was demonstrated against carrageenan induced edema in the rat paw.

分子量

494.56

Formula

C₂₂H₂₃FN₂O₆S₂

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.